ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic

By sjmartinez • October 31, 2024

Keshtkar-Jahromi M, Anstrom KJ, Barkauskas C, Brown SM, Daar ES, Fischer W, Gibbs KW, Higgs ES, Hughes MD, Jagannathan P, LaVange L, Lindsell CJ, Nayak SU, Paredes R, Parmar M, Peltan ID, Proschan M, Shotwell MS, Vock DM, Yokum T, Adam SJ. ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic. J Clin Transl Sci. 2024 Oct 15;8(1):e151. doi: 10.1017/cts.2024.1. PMID: 39478775; PMCID: PMC11523015.

Tags: ACTIV, Clinical Trial, covid-19, design, Infectious Diseases, lessons, Publications

Related Posts

Author Correction: Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors

Doni Jayavelu N, Samaha H, Wimalasena ST, Hoch A, Gygi JP, Gabernet G, Ozonoff A, Liu S, Milliren CE, Levy O, Baden LR, Melamed E,[...]

The HosA histone deacetylase regulates stress resistance, host cell interactions, and virulence in Aspergillus fumigatus

Liu H, Lee P, Vo A, Paul S, Phan QT, Lin J, Bruno VM, Stamnes MA, Moye-Rowley WS, Filler SG. The HosA histone deacetylase regulates[...]

The Medicine for a Changing Planet curriculum: a mixed methods evaluation

Benzekri NA, Tin AH, Judson SD, Ripp K, Xie M, Veidis E, Barry M, Rabinowitz P. The Medicine for a Changing Planet curriculum: a mixed[...]